Jordi Quintana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jordi Quintana has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ana Gimeno
CIC bioGUNE , Bizkaia Technology Park, Building 801A, 48170 Derio, Spain
1 shared publicationDaniel Blasi
Plataforma Drug Discovery, Parc Científic de Barcelona (PCB), Baldiri Reixac 10, 08028 Barcelona, Spain
1 shared publication- Ellen Y. Cotrina
Institut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.), 08034 Barcelona, Spain
1 shared publication - Gemma Arsequell
IQAC-CSIC
1 shared publication Gregorio Valencia
Institut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.), 08034 Barcelona, Spain
1 shared publication- Isabel Cardoso
I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 16 June 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (13) , 5749-5758
Insights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal
Several strategies against Alzheimer disease (AD) are directed to target Aβ-peptides. The ability of transthyretin (TTR) to bind Aβ-peptides and the positive effect exerted by some TTR stabilizers for modulating the TTR–Aβ interaction have been previously studied. Herein, key structural features of the interaction between TTR and the Aβ(12–28) peptide (3), the essential recognition element of Aβ, have been unravelled by STD-NMR spectroscopy methods in solution. Molecular aspects related to the role of the TTR stabilizer iododiflunisal (IDIF, 5) on the TTR–Aβ complex have been also examined. The NMR results, assisted by molecular modeling protocols, have provided a structural model for the TTR–Aβ interaction, as well as for the ternary complex formed in the presence of IDIF. This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms observed in AD/TTR± animal models after IDIF treatment and eventually for designing new molecules toward AD therapeutic drugs.
- 16 June 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (13) , 5749-5758
Open AccessInsights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal
Several strategies against Alzheimer disease (AD) are directed to target Aβ-peptides. The ability of transthyretin (TTR) to bind Aβ-peptides and the positive effect exerted by some TTR stabilizers for modulating the TTR–Aβ interaction have been previously studied. Herein, key structural features of the interaction between TTR and the Aβ(12–28) peptide (3), the essential recognition element of Aβ, have been unravelled by STD-NMR spectroscopy methods in solution. Molecular aspects related to the role of the TTR stabilizer iododiflunisal (IDIF, 5) on the TTR–Aβ complex have been also examined. The NMR results, assisted by molecular modeling protocols, have provided a structural model for the TTR–Aβ interaction, as well as for the ternary complex formed in the presence of IDIF. This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms observed in AD/TTR± animal models after IDIF treatment and eventually for designing new molecules toward AD therapeutic drugs.